The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
Recruiting
- Conditions
- Coronary Heart Disease, Susceptibility to, 1
- Interventions
- Other: No intervention
- Registration Number
- NCT05945394
- Lead Sponsor
- Nanjing Medical University
- Brief Summary
To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human
- Detailed Description
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- Patients with suspected coronary heart disease
- patients received coronary angiography
Exclusion Criteria
- NYHA III-IV
- malignant tumor
- acute infection
- thyroid dysfunction
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with suspected CHD who experienced CAG No intervention Patients with suspected coronary heart disease who experienced coronary angiography
- Primary Outcome Measures
Name Time Method stenosis of coronary artery 1 week The stenosis of coronary artery based on the results of coronary angiography
- Secondary Outcome Measures
Name Time Method coronary artery calcium 1 week The coronary artery calcification based on the results of coronary angiography
Trial Locations
- Locations (1)
Huai'an First People's Hospital
🇨🇳Huai'an, Jiangsu, China